![1]()
News
Aspirin plus a DOAC may do more harm than good in some
December 8, 2019
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication increased bleeding risks in a large cohort.
![1]()
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
News
What’s new in hepatitis C: Four themes that dominated at the Liver Meeting
November 22, 2019
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy, benefits of sustained virologic response, preemptive therapy in donor-positive organ transplant.
![1]()
News
CDC releases update of 2013 Antibiotic Resistance Threats Report
November 14, 2019
The report includes the hopeful news that there were 42 new antibiotics in development as of June 2019.
News
Dapagliflozin approved for reducing HF hospitalization in diabetes
October 21, 2019
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
![1]()
News
Certain diabetes drugs may thwart dementia
October 21, 2019
COPENHAGEN – Intriguing findings from a Danish national registry study.
![1]()
News
Hospital-acquired C. diff. tied to four ‘high-risk’ antibiotic classes
September 16, 2019
High-risk antibiotics included second-, third-, and fourth-generation cephalosporins, fluoroquinolones, carbapenems, and lincosamides.
![1]()
Article
Short Takes
September 12, 2019
In The Literature's Short Takes
News
Drug doses for heart failure could possibly be halved for women
September 12, 2019
Women reached the highest level of drug efficacy at half the doses of ACE inhibitors or ARBs and beta-blockers needed by men to reach the same level.
![1]()
News
Standardized communication may prevent anticoagulant adverse drug events
September 2, 2019
What information is needed on discharge to reduce anticoagulant adverse drug events (ADEs)?
